The von Hippel-Lindau tumour suppressor gene (VHL) targets hypoxia inducible factor (HIF)-a subunits for ubiquitin dependent proteolysis. To better understand the role of this and other putative pathways of gene regulation in VHL function we subjected mRNA from VHL defective renal carcinoma cells and transfectants re-expressing a wild type VHL allele to dierential expression pro®ling, and analysed VHL target genes for oxygen regulated expression. Among a group of newly identi®ed VHL target genes the majority but not all were regulated by oxygen, indicating that whilst dysregulation of the HIF system makes a dominant contribution to alterations in transcription, VHL has other in¯uences on patterns of gene expression. Genes newly de®ned as targets of the VHL/hypoxia pathway (conditionally downregulated by VHL in normoxic cells) include aminopeptidase A, collagen type V, alpha 1, cyclin G2, DEC1/Stra13, endothelin 1, low density lipoprotein receptor-related protein 1, MIC2/CD99, and transglutaminase 2. These genes have a variety of functions relevant to tumour biology. However, not all are connected with the promotion of tumour growth, some being pro-apoptotic or growth inhibitory. We postulate that co-ordinate regulation as part of the HIF pathway may explain this paradox, and that evolution of antiapoptotic pathways may be required for tumour growth under VHL-dysregulation. Our results indicate that it will be necessary to consider the eects of abnormal activity in integral regulatory pathways, as well as the eects of individual genes to understand the role of abnormal patterns of gene expression in cancer. Oncogene (2000) 19, 6297 ± 6305.
Introduction
Tumour suppressor genes and oncogenes are often involved, directly or indirectly, in the regulation of transcription. New opportunities for large-scale analysis of the downstream patterns of abnormal gene expression (Schena et al., 1995; Iyer et al., 1999) may therefore provide important insights into the underlying processes which promote the development of cancer.
Germline mutations in the von Hippel-Lindau (VHL) tumour suppressor gene are associated with a dominantly inherited cancer syndrome, in which inactivation or loss of the remaining wild type allele as a somatic event results in the formation of typically hypervascularized neoplasms involving the kidney, retina, pancreas, adrenal gland and central nervous system (Kaelin and Maher, 1998) . In addition, somatic inactivation or mutation of both VHL alleles is observed in the majority of sporadic renal cancers (Gnarra et al., 1994) . Recent work has connected the function of the gene product, pVHL, with regulation of the transcriptional response to hypoxia. pVHL forms part of a ubiquitin ligase complex (Iwai et al., 1999; Lisztwan et al., 1999) that targets the regulatory a subunits of hypoxia inducible factor-1 (HIF-1) for oxygen dependent proteolysis (Maxwell et al., 1999; Cockman et al., 2000) . HIF-1 is a heterodimeric DNA binding complex that directs the expression of a large family of hypoxia inducible genes including members involved in glucose transport, glycolysis, and angiogenesis (Shweiki et al., 1992; Semenza et al., 1994; Ebert et al., 1995) . In VHL defective cells, HIF-a subunits are constitutively stabilized leading to activation of the transcriptional complex and its target genes irrespective of oxygen concentration (Maxwell et al., 1999) .
The direct targeting of a hypoxia inducible pathway that is most clearly linked with the regulation of metabolism and angiogenesis is unusual amongst tumour supressor genes. Though upregulation of angiogenic growth factors provides an explanation for the angiogenic phenotype of VHL syndrome, the role of HIF activation in other aspects of oncogenesis is less clear. HIF might have other targets that could illuminate such a role, or pVHL might have functions other than HIF regulation that are relevant to its tumour suppressor function (Ohh et al., 1998; Pause et al., 1998; Iwai et al., 1999) .
We therefore sought to expand our understanding of the patterns of gene expression that are aected by pVHL, and to determine the extent to which these genes are also subject to regulation by oxygen. We employed a glass-chip based cDNA array of 9182 unbiased genes and ESTs to compare the gene expression pro®le in stable transfectants of the renal cell carcinoma (RCC) line, RCC4, that were either defective or competent for pVHL. Regulation by pVHL was con®rmed by ribonuclease protection assay both in the original pair of RCC4 cell lines, and a second pair of transfectants based on another VHL defective RCC line, 786-0. We demonstrate the reproducibility of the screen, and show that for the large majority of genes identi®ed by the screen, dierential expression could be con®rmed by ribonuclease protection assay. For about 50% of the identi®ed genes, a similar pattern of dierential expression in relation to VHL status was apparent in both cell backgrounds. The majority of these genes were also regulated by hypoxia in multiple non-renal cell types, therefore de®ning several new classes of hypoxia/pVHL responsive genes. In addition, other genes were de®ned whose expression was responsive to pVHL but not to hypoxia, indicating that pVHL may in¯uence additional pathways of gene expression that are not regulated by hypoxia.
Results

Analysis of VHL dependent expression by gene expression microarray
To examine the eects of the tumour suppressor gene VHL on global patterns of gene expression we employed an mRNA dierential screen of 9182 unique clones using a Gene Expression Microarray (GEM) based on competitive hybridization expression pro®ling (Incyte Genomics). Of the 9182 cDNA clones, 8481 are unique annotated genes. We compared mRNA from stable transfectants of the pVHL de®cient renal carcinoma cell line RCC4 expressing vector backbone alone (RCC4) or wild type human pVHL (RCC4/ VHL). To test the reproducibility of the screen, the procedure was carried out on a second independently derived pair of mRNA samples extracted from RCC4 and RCC4/VHL cells. Figure 1 shows expression data for 30 genes showing the greatest induction or repression by transfection of VHL in the ®rst screen plotted against expression data for the same cDNAs in the second screen. There was a good correlation, though quantitative dierences between the screens in the amplitude of expression were commonly observed.
RNAse protection analysis of VHL dependent gene expression in different renal cell carcinoma cell lines GEM analysis identi®ed 22 genes that were consistently repressed by VHL in both screens by an average of twofold or greater. For these genes, riboprobe templates were constructed to permit accurate quanti®cation of mRNA regulation by ribonuclease protection assay (RPA). Two dierent sets of renal cell carcinoma transfectants were studied, the original pair of RCC4 and RCC4/VHL transfectants, and a similar pair of 786-0 transfectants expressing vector backbone alone or wild type human pVHL (786-0 and 786-0/VHL). Results are summarized in Table 1a . Of the 22 genes identi®ed by GEM screening, 20 were con®rmed by RPA as showing a clear reduction in expression in RCC4/VHL cells versus RCC4 cells, whereas two genes were not expressed at levels quanti®able by RPA. Interestingly, for many genes the amplitude of dierential mRNA expression demonstrated by RPA was substantially underestimated by GEM analysis. Of the 20 genes showing repression by re-expression of VHL in RCC4, seven were also repressed by re-expression of VHL in 786-0, ®ve were not expressed at levels quanti®able by RPA in 786-0 cells, and eight were expressed but not in¯uenced by re-expression of VHL in this background. In addition to the genes which were downregulated by VHL, GEM analysis of the RCC4 transfectants also identi®ed a similar number of genes that were upregulated by re-expression of VHL (Figure 1 ). Those ®ve showing the largest amplitude of dierential expression were selected for further analysis by RPA. Results are summarized in Table 1b . Again the GEM results were largely reproduced by RPA, with four of the ®ve genes showing clearly increased levels of expression in RCC4/VHL. When these four genes were assayed in the 786-0 transfectants, one was clearly induced by re-expression of VHL, whereas one was not expressed at levels quanti®able by RPA, and two were expressed but not in¯uenced by re-expression of VHL in this background.
Oxygen responsiveness of VHL regulated genes
The above assay de®ned several new genes that are regulated by VHL. We next wished to determine the extent to which these newly de®ned VHL responsive genes were regulated by the hypoxia pathway. The pairs of transfectants of RCC4 and 786-0 cells were therefore exposed in parallel to normoxia (20% O 2 ) or hypoxia (0.1% O 2 ) for 16 h.
Ribonuclease protection assays were performed for all genes that were downregulated by VHL in both RCC4 and 786-0 cells, or downregulated by VHL in RCC4 cells but not expressed in 786-0 cells (n=12). Results are illustrated in Figure 2a ± c, and summarized in Table 2a . In total, eight of these genes (endothelin 1 (EDN1), dierentiated embryo chrondocyte 1 (DEC1), monoclonal, Imperial Cancer Research Fund 2 (MIC2), transglutaminase 2 (TGM2), low density lipoprotein receptor-related protein 1 (LRP1), collagen type V, alpha 1 (COL5A1), cyclin G2 (CCNG2), and aminopeptidase A (APA)), were reproducibly induced at least twofold by hypoxia in one or both transfectants re-expressing VHL (Figure 2a,b) . In each case upregulation in the corresponding VHL de®cient control transfectant was associated with loss of a hypoxic response. For the remaining four genes (vimentin (VIM), secretory granule neuroendocrine protein 1 (SGNE1), spermidine N1-acetyltransferase (SAT), and keratin, hair, basic, 1 (KRTHB1)) responses to hypoxia were small or absent ( Figure 2c ).
All four genes that were upregulated by VHL reexpression in RCC4 cells were examined for responses to hypoxia in a similar manner, and results are illustrated in Figure 2d and summarized in Table 2b . Two of these genes (cathepsin C (CTSC) and keratin 18 (K18)) were repressed by hypoxia in RCC4/VHL. Interestingly these responses were not seen in the 786-0 background where the genes also appeared unresponsive to VHL. Two genes (EST (Incyte ID: 1797836) and I factor (IF)) were unresponsive to hypoxia in either cellular background. ATPase Na+/K+ transporter, beta 3 2.4 NR NR NE: gene is not expressed at levels quanti®able by ribonuclease protection assay (RPA); NR: gene is expressed although not regulated by VHL by at least twofold. Fold regulation as determined by array screening is the average of two independent arrays. Fold regulation as determined by RPA was calculated by quanti®cation of the protected species, and standardized to an internal control, the constitutively expressed U6 small nuclear RNA. Four genes were regulated by VHL to an excess of 50-fold, above which, quanti®cation is less reliable and therefore labelled as 450
Oxygen dependent expression in non-renal cell types
Of the eight genes de®ned above as showing hypoxia inducible responses in VHL competent cells, endothelin 1 is the only gene whose hypoxic response has been studied extensively. To examine whether these newly described responses to hypoxia were observed generally, we examined their hypoxia inducible expression in cell lines derived from lung (A549), bladder (EJ-28) and breast (HBL-100) tissues. Results are illustrated in Figure 3 . Five of the genes (DEC1, MIC2, TGM2, LRP1, and CCNG2) were induced by hypoxia in each of the three cell lines. APA was not expressed in any of the three nonrenal cell lines, whilst COL5A1 was strongly induced by hypoxia in HBL100 but not expressed in A549 or EJ-28.
Expression in HIFa deficient cells
Taken together with the function of pVHL in the oxygen regulated proteolysis of HIF-a subunits, the above results strongly suggested that the eight genes that were identi®ed as being both downregulated by pVHL in normoxic cells and upregulated by hypoxia in VHL-competent cells, and the two which are regulated by both stimuli in the opposite direction, are responding directly or indirectly to HIF. To con®rm this for two widely expressed genes, DEC1 and CCNG2, we constructed riboprobes to the homologous Chinese hamster genes and tested expression in a wild type Chinese hamster ovary subline (C4.5), and a mutant derivative (Ka13) which is functionally defective in HIF-1a (Wood et al., 1998) . Both genes showed strong induction by hypoxia in C4.5 cells, which was abolished in the HIFa de®cient Ka13 cells (Figure 4 ).
Discussion
We have used a glass-chip array to examine the dierences in mRNA expression resulting from stable mRNA differential expression profiling to identify VHL target genes CC Wykoff et al transfection of wild type pVHL into a VHL defective renal carcinoma cell line. Using a signi®cance threshold of twofold dierential expression we de®ned a number of new genes that are regulated either negatively or positively by VHL, and have shown that the majority, but not all, are responsive to hypoxia. Based on veri®cation by ribonuclease protection assay, GEM screening identi®ed VHL regulated genes with a low false positive rate. However, several indicators suggested that the screens may have considerably underestimated the number of genes which are regulated in this way. First, for several genes the quantitative mRNA analyses by ribonuclease protection demonstrated a substantially greater amplitude of regulation than that indicated by the GEM screens. Second, several genes known to be strongly regulated by VHL, such as LDH-A (Maxwell et al., 1999) and VEGF (Illiopoulos et al., 1996) , showed regulation in the GEM screens below the arbitrary signi®cance threshold of twofold dierential expression that we used to select genes for further study. This occurred despite the demonstration of substantially greater levels of regulation for these genes by ribonuclease protection assay in the mRNA samples used for GEM screening (data not shown). Thus, using this threshold it is clear that the GEM screening for VHL targets had a substantial false negative rate. Taken together with the number of con®rmed VHL targets from a screen of 9182 genes, this suggests that the total number of targets whose expression is regulated directly or indirectly by VHL is likely to be large, perhaps ranging into hundreds of genes. This possibility is also supported by comparison of our data with other recently published screens for either VHL regulated, or hypoxia regulated genes, in that only limited overlap is observed. Thus only DEC1/Stra 13 (Ivanov et al., 1998) and vimentin (Moch et al., 1999) have previously been identi®ed as upregulated in VHL de®cient cells, whereas LRP1 was the only gene identi®ed in common with a recent array screening for hypoxia inducible genes in cervical and other squamous carcinoma cells (Koong et al., 2000) .
Analysis of expression in two sets of renal cell carcinoma transfectants that were either VHL defective, or competent was used to de®ne a core group of VHL responsive genes which were regulated by VHL in both sets of transfectants. Surprisingly, a substantial number of genes that were identi®ed as regulated by VHL status in the RCC4 transfectants were either not aected by VHL or not expressed at all in the 786-0 transfectants. Such a result might arise if there were clonal dierences between the RCC4 and RCC4/VHL cells that were unrelated to VHL status, or if the range of VHL responsive genes were dierent in the two renal carcinoma lines. Support for the latter possibility was obtained for one subset of genes. Thus for some genes that were dierentially expressed in accordance with VHL status in the RCC4 transfectants, but not expressed at quanti®able levels in the 786-0 cells, striking responses to hypoxia were observed in several cell backgrounds. Since VHL has a critical function in the responses to hypoxia through regulation of HIF-a (Maxwell et al., 1999) this provides independent evidence that these genes are likely to be genuine VHL targets in many cell types. Thus the results suggest that inactivation of a tumour suppressor gene may have substantially dierent eects on gene expression even in closely similar cell backgrounds. Dierences between RCC4 and 786-0 cells in the residual function of mutant VHL alleles, dierential expression of HIF-1a and HIF-2a subunits, or other genetic dierences aecting transcriptional availability of potentially responsive genes are all possible explanations. Following the recognition that pVHL has a critical function in the regulation of HIF-a, it has become clear that genes already de®ned as HIF targets will commonly be upregulated in VHL defective cells. However to understand more completely the role of the HIF pathway in VHL disease it is necessary to consider the converse relationship; that is, to de®ne the extent to which global eects of VHL status on gene expression patterns are mediated through activation of the hypoxia pathway. Therefore an important aim of the study was to test for regulation by oxygen among genes that were newly identi®ed as responsive to VHL status. Of a total of 16 such genes tested for regulation by oxygen, the majority (10/16) showed greater than twofold regulation by hypoxia in VHL competent cells. Of the remaining six genes, vimentin showed slight (1.9-fold) induction by hypoxia in RCC4/VHL cells, whereas the other ®ve genes showed little or no regulation by oxygen. For three genes this occurred despite regulation by VHL in both cell backgrounds. Two of these genes, secretory granule neuroendocrine protein 1 and spermidine N1-acetyltransferase, were downregulated by VHL, and one, an EST, was upregulated by VHL. Taken together these results indicate that the role of VHL in regulation of the HIF pathway makes a dominant contribution to the overall pattern of altered gene expression in VHL defective cells. However, the results also indicate that pVHL most likely has other functions which impinge on patterns of gene expression, and which will need to be considered in the analysis of its role as a tumor suppressor.
Though the functions of several of the VHL regulated genes de®ned in this study are incompletely understood, a number have known functions which are of interest in relation to the biology of tumour formation. For instance endothelin 1 is a hypoxia inducible HIF-1 target gene (Hieda and GomezSanchez, 1990; Hu et al., 1998) capable of stimulating proliferation and migration, inducing VEGF production (Okuda et al., 1998; Kozawa et al., 2000) , and increasing the expression of various proto-oncogenes (Yin et al., 1992; Herman and Simonson, 1995) . Interestingly, several of the VHL regulated genes have potential roles in matrix metabolism. LRP1 is a large endocytic receptor that mediates the catabolism of a number of molecules important in vascular biology (Strickland et al., 1995) , and appears to play a role in regulation of cell motility (Okada et al., 1996; Chazaud et al., 2000) . MIC2/CD99 is a cell surface glycoprotein involved in cell adhesion (Hahn et al., 1997) that is commonly expressed in haematological neoplasms (Soslow et al., 1997; Zhang et al., 2000) and upregulated in Ewing family tumours (Zoubek et al., 1995) . Transglutaminase 2, otherwise known as tissue transglutaminase, is a multifunctional protein capable of activating phospholipase C and catalyzing the crosslinking of extracellular proteins through the formation of e-(g-glutamyl)lysine cross-links (for review see Chen and Mehta, 1999) .
In some cases the identi®ed gene forms part of a large family and it seems likely that several members may be co-ordinately regulated by the hypoxia pathway. For instance, regulation of collagen type V, alpha 1 may form part of a more general response of collagen metabolism to the hypoxia pathway. Prolyl 4-hydroxylase alpha 1, a key enzyme in collagen biosynthesis, has recently been identi®ed as a HIF-1 dependent hypoxia inducible gene (Takahashi et al., 2000) . Aminopeptidase A is an ectopeptidase member of the peptidase family m1 proposed to play a role in the progression of cervical neoplasms (Fujimura et al., 2000) . Interestingly, its expression in tissue culture correlates with resistance of renal carcinoma cells to the antiproliferative eects of alpha-interferon (Nanus et al., 1993) . Aminopeptidase A shows a 54% identity to aminopeptidase N, a gene recently found to promote invasion and to be expressed on proliferating endothelial cells undergoing angiogenesis (Pasqualini et al., 2000) .
For several genes de®ned in the screen and demonstrated to show a high level of induction by hypoxia, it is dicult to understand the role in tumour promotion. For instance cyclin G2 is a member of the G class of cyclins (Horne et al., 1996) , which are unusual amongst cyclins so far described in having a cell cycle inhibitory eect. Its expression is increased in response to DNA damaging agents, dierentiation signals and growth inhibitory drugs (Bates et al., 1996; Horne et al., 1997) . DEC1/Stra13 (Shen et al., 1997) , is a transcriptional repressor whose expression is associated with induction of growth arrest and terminal dierentiation (Boudjelal et al., 1997; Sun and Taneja, 2000) . Furthermore, in addition to its role in matrix cross linking, increased expression of transglutaminase 2 characterizes cells undergoing apoptosis, and inhibition protects against several apoptotic stimuli (Oliverio et al., 1999 and references within) .
Thus for many genes, known functions are not easily accommodated into a simple model of tumour promotion by upregulated expression following VHL inactivation. Such genes may have other as yet unrecognized functions. However, the demonstration that many of the genes are upregulated in parallel as a consequence of dysregulation of the HIF pathway provides another potential explanation for this paradox. Such genes must normally form part of a coordinated physiological response to hypoxia that might well, in the context of tumour growth, have both proand anti-tumorigenic eects. For instance the physiological response to hypoxia might include limitation of cellular proliferation under hypoxic conditions (Graeber et al., 1994) . In relation to this possibility it is of interest that dierent studies of tumour xenografts of HIF de®cient cells have demonstrated enhanced (Carmeliet et al., 1998) , as well as reduced (Maxwell et al., 1997; Ryan et al., 1998) tumour growth. Balancing eects of dierent genes upregulated as part of a pathway of co-ordinate physiological regulation might also contribute to the tissue speci®city of the VHL tumour syndrome. Furthermore, our results suggest that selection of cells capable of evading growth-inhibition/apoptosis is likely to be an early step in VHL-mutant associated tumour progression.
In summary these studies have demonstrated, using an unbiased set of newly identi®ed genes that are responsive to VHL, that activation of the HIF system makes a quantitatively dominant contribution to the changes in gene expression associated with the VHL status of renal carcinoma cells. Most probably, however, VHL status exerts eects on gene expression through other pathways. Further studies of the new classes of VHL regulated and HIF regulated genes will be of interest both in understanding VHL associated tumours and the role of microenvironmental hypoxia in other types of cancer.
Materials and methods
Cell lines
Stable RCC4 transfectants expressing vector backbone alone or wild type pVHL were as described (Maxwell et al., 1999) . Stable transfectants of 786-0 cells expressing vector backbone alone or wild type pVHL were a gift from WG Kaelin. A549, EJ-28, and HBL-100 cell lines were from ECACC. Chinese hamster ovary parental cell line, C4.5, and the HIF-1a de®cient derivative, Ka13, were as described (Wood et al., 1998) . Cells were grown in DMEM (Sigma) supplemented with 10% foetal calf serum (Globepharm), L-glutamine (2 mM), penicillin (50 IU/ml), and streptomycin sulphate (50 mg/ml). Studies of inducible gene expression were performed on cells approaching con¯uence in normal growth medium for 16 h. Parallel incubations were performed on aliquots of cells in normoxia (humidi®ed air with 5% CO 2 ) or hypoxia. Hypoxic conditions were generated in a Napco 7001 incubator (Precision Scienti®c) with 0.1% O 2 , 5% CO 2 , and balance N 2 .
Gene expression microarray (GEM) screening mRNA was extracted and puri®ed using oligo-dT (Dynal) beads according to manufacturer's instructions. 600 ng of each mRNA sample was reverse transcribed into cDNA and labelled with either Cy3 or Cy5¯uorescent dye and applied to a competitive hybridization Human UniGEM V 1.0 by Incyte Genomics. Data were analysed using GEMTools TM software.
RNA analysis
For ribonuclease protection assays (RPA), total RNA was extracted by a modi®ed acid/guanidinium thiocyanate/ phenol/chloroform method (RNAzol B, Cinna/Biotec Laboratories), and dissolved in hybridization buer (80% formamide, 40 mM PIPES, 400 mM sodium chloride, and 1 mM EDTA, pH8). To generate riboprobe templates, cDNA fragments of human genes were cloned by reverse transcription-PCR and ligated into pSP72 (Promega). For details of fragments cloned for each gene, see Appendix. The identities of the cloned fragments were con®rmed by nucleotide sequence analysis. DNA templates for generating 32 P-labelled RNA probes were linearized for 16 h with BglII and transcribed using SP6 RNA polymerase. Quanti®cation of the protected species was performed using a phosphoimager (Molecular Dynamics), and related to an internal control assay for the constitutively expressed U6 small nuclear RNA (LC), performed for each assay as described (Maxwell et al., 1999) . Glucose transporter-1 mRNA assays were used as a positive control for the conditions of hypoxic stimulation. Independent aliquots of 30 mg were analysed for each gene.
Abbreviations VHL, von Hippel-Lindau; HIF-1, hypoxia inducible factor-1; RCC, renal cell carcinoma; RPA, ribonuclease protection assay; GEM, gene expression microarray; LC, U6 small nuclear RNA; GLUT-1, glucose transporter 1; VEGF, vascular endothelial growth factor; EDN1, endothelin-1; DEC1, dierentiated embryo chrondocyte 1; Stra13, stimulated with retinoic acid 13; MIC2, monoclonal, Imperial Cancer Research Fund 2; TGM2, transglutaminase 2; LRP1, low density lipoprotein receptorrelated protein 1; COL5A1, collagen type V, alpha 1; CCNG2, cyclin G2; APA, aminopeptidase A; VIM, vimentin; SGNE1, secretory granule neuroendocrine protein 1; SAT, spermidine N1-acetyltransferase; KRTHB1, keratin, hair, basic, 1; CTSC, cathepsin C; K18, keratin 18; EST, expressed sequence tag; IF, I factor; CHO, Chinese hamster ovary.
